All In Biotech

Drug Trial Radar · NCT05177835

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

203

Planned (sponsor's estimate)

Start

Dec 3, 2021

Primary completion

Mar 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Abivax S.A.Industry
Sponsor type
Industry
First posted
Jan 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment. All subjects will receive ABX464 given at 25 mg QD. The enrolment in this long-term study will be based on the endoscopic improvement, the willingness of the subject to carry on his/her participation and also based on investigator's judgement. Subjects will be treated with ABX464 for a maximum period of 54 months. Subjects will be followed up quarterly. After the treatment period, subjects will be followed for 4 additional weeks for safety purposes.

Conditions

  • Ulcerative Colitis

Interventions

  • ABX464Drug

    All subjects will receive ABX464 given at 25 mg QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse events in ABX464 treated subjectsTime frame: From Baseline to a maximum period of 78 months

Locations

46 sites in 14 countries. Site status is shown where the registry gives one.

  • Medizinische Universitaet Innsbruck

    Innsbruck, Austria

  • Medical University of Vienna

    Vienna, Austria

  • Antwerp University Hospital

    Antwerp, Belgium

  • UZ Leuven

    Leuven, Belgium

  • South Edmonton Gastroenterology

    Edmonton, Canada

  • Fakultni nemocnice u sv. Anny v Brne

    Brno, Czechia

  • Nemocnice Slany

    Slaný, Czechia

  • Centre Hospitalier Universitaire Grenoble Alpes

    Grenoble, France

  • Centre Hospitalier Universitaire De Montpellier

    Montpellier, France

  • CHU Nantes - Hôtel Dieu

    Nantes, France

  • Institut des MICI

    Neuilly-sur-Seine, France

  • CHU Saint Etienne - Hôpital Nord

    Saint-Etienne, France

  • Goethe University Frankfurt

    Frankfurt, Germany

  • Studiengesellschaft BSF UG (haftungsbeschraenkt)

    Halle, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • DRC Gyogyszervizsgalo Kozpont Kft.

    Balatonfüred, Hungary

  • Semmelweis University

    Budapest, Hungary

  • Vasutegeszseguegyi Nonprofit Koezhasznu Kft.

    Debrecen, Hungary

  • Győr-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház I. Belgyógyászat

    Győr, Hungary

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • Humanitas Mirasole S.p.A.

    Rozzano, Italy

  • IRCCS Ospedale Sacro Cuore Don Calabria

    Verona, Italy

  • Centrum Medyczne Plejady

    Krakow, Poland

  • Samodzielny PZOZ w Lecznej

    Łęczna, Poland

  • Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. i M. Nastaj sp. p

    Lublin, Poland

  • Wojskowy Szpital Kliniczny w Lublinie

    Lublin, Poland

  • Medicome Sp. z o. o.

    Oświęcim, Poland

  • Trialmed CRS

    Piotrkow Trybunalski, Poland

  • Termedia Sp. z o.o (NSZOZ Termedica - Centrum Badan Klinicznych)

    Poznan, Poland

  • Ośrodek Badań Klinicznych "METABOLICA"

    Tarnów, Poland

  • Medical Network Sp. z o.o.

    Warsaw, Poland

  • Santa Sp. z o.o.

    Warsaw, Poland

  • Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska

    Wroclaw, Poland

  • Centrum Medyczne Oporow

    Wroclaw, Poland

  • LexMedica

    Wroclaw, Poland

  • Kliničko bolnički centar Zvezdara

    Belgrade, Serbia

  • Opšta bolnica "Đorđe Joanović" Zrenjanin Odsek za gastroenterologiju

    Zrenjanin, Serbia

  • Cliniq s.r.o.

    Bratislava, Slovakia

  • GASTRO I, s.r.o.

    Prešov, Slovakia

  • Endomed s.r.o

    Vranov nad Topľou, Slovakia

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.